IBD Nurses Research Articles

The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19.

The role of nurses has great educational-scientific potential in COVID-19 vaccination. The aim of this work is to clarify whether the educational role of IBD nurses in vaccination is perceived by IBD patients. A cross-sectional study was carried out, through a questionnaire, to evaluate how many IBD patients received health education about vaccinations from the dedicated nurses (IBD nurses). There were four hundred questionnaires, 310 patients (77.5%) answered all questions. The nurse does not appear to help educate patients on influenza vaccination (66.1%) or pneumococcal vaccination (81.6%). Disclosed patients have many doubts about the new COVID-19 vaccination (74.4%) and many seek information (74.8%) and think that the nurse can provide the necessary information (70%). IBD nurses do not seem very active in the vaccination education role, and they do not meet patients' expectations, which are conversely very high.

N03 Information flow experiences during COVID-19 in IBD patients: a prospective observational study

BackgroundDuring the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several patients contacted members of the IBD team with coronavirus disease 2019 (COVID-19) related questions. Some patients intended to cancel scheduled IBD clinic outpatient visits or endoscopic examinations and/or stop or postpone their medication. We surveyed the need for information by IBD patients during the SARS-CoV-2 pandemic and the role of the IBD team in this regard.MethodsWe performed an anonymous survey at the IBD department of our tertiary referral center. The questionnaire contained 15 closed questions, including on basic demographic data, medication use, testing for COVID-19, information sources, and intention to stop or postpone medication or follow-up. The questionnaire was available to all adult patients attending the IBD outpatient clinic and infusion unit from July 1st until October 30th 2020. All questionnaires were collected before the second COVID-19 wave. Patients on subcutaneous medication that did not attend the IBD clinic during these months were contacted via e-mail.ResultsWe collected 965 questionnaires. The majority of patients (44.3%) was 18–40 years old. There were more patients with Crohn’s disease (66%) than ulcerative colitis (32%) and IBD unclassified (2%). Demographics and medication use are presented in table 1. A third of the patients (31.7%) was tested for SARS-CoV-2, of whom 8.3% tested positive. Twenty-six percent of patients considered they had higher need for information about COVID-19 than the general population. News websites were a source of information about COVID-19 for 52.5% of patients, followed by hospital websites (43.8%), direct contact with the IBD physician (24.6%), direct contact with the IBD nurse (23.1%), and state sponsored websites (20.9%). In fact, 35.9% of patients contacted the IBD nurse since the start of the pandemic. The majority of patients reported they were satisfied by the information (80.5%) and/or reassured (85%) by the IBD nurse. Ten percent of patients had considered to stop IBD medication due to the pandemic, and 80% of these refrained to do so following the advice of the IBD nurses. Finally, 12.5% of the patients expressed true fear of hospital visits due to the pandemic, which was associated with female gender and higher need for information.ConclusionTreatment cessation and anxiety could be avoided by direct interaction with the IBD nurses and in particular with the IBD nurse as first point of contact for the patient. Patients with IBD may profit from an optimized information platform with scientifically correct information addressing the concerns of this specific population.

N10 Experience with telemedicine during the COVID-19 pandemic and preferences for future e-health in a large IBD cohort

BackgroundThe COVID-19 pandemic affects clinical care, daily life and wellbeing of patients with IBD. During the contact restrictions, we realized anxiety among our IBD patients and unmet needs for healthcare. We investigated patient’s experience with telemedicine (TM) during the pandemic, their interest in future TM use, and their preference regarding a qualified IBD Nurse-led or a Medical Doctor-led (MD-led) teleconsultation at a large German IBD center.MethodsPediatric and adult patients who attended the IBD unit at least once between 7/2018 and 6/2020) were invited to a prospective survey (KoCo19-CED-1). Questions included items on IBD (phenotype, treatment and disease activity), comorbidities, healthcare utilization, demographic and socioeconomic factors, psychological burden and IBD-related quality of life during the COVID-19 pandemic. This sub-analysis presents patient’s experience with TM and their preference for a contact with an IBD Nurse.ResultsOf 820 identified IBD cases, 504 (62%) patients and/or their parents completed the survey between mid-July to mid-October 2020; 86 were children (aged 6 to 18 years) and 418 were adults (up to 85 years); 58.7% had Crohn’s disease and 35.7% Ulcerative Colitis. Current treatment with any immunosuppressive medication (mono- or combo-therapy with immunomodulators, biologics, JAK-inhibitors and/or corticosteroids) were reported by 79.6% (401/504) of patients. During the pandemic, an in-person visit was substituted with TM by an IBD Nurse or a medical doctor (MD) in 58 (11.6%) and 29 (5.8%) of the patients, with high satisfaction (88.5% vs 92.1 %, respectively, n.s.). Half of the patients (n=246) showed interest in future TM, thereof 60.2% preferred consultation with a MD, 1,6% with an IBD Nurse and 38.2% expressed no preference. Of patients with prior experience with an IBD Nurse-led TM (n=38), 96% are interested to use TM in the future. Rejection of future TM was related to no TM experience (p=0.001), having Crohn’s disease (p=0.032), receiving biologics (p=0.004), and self- or non-employment status (p=0.003), but not to gender, age, self-reported disease activity or disease duration.ConclusionPatient acceptance of TM is high, particular in those with previous TM experience, regardless of performed by MD or IBD Nurse. Our data support the statement on e-health in the N-ECCO 2018 Consensus giving an advanced IBD Nurse alongside with MD a key role to improve IBD care.

P242 Newly diagnosed Inflammatory Bowel Disease patients referred via the Straight To Test Lower GI two week wait pathway, Single Centre Study

Abstract Background Fast track or 2-week wait Lower GI pathways (2ww LGI), including Straight To Test or Straight To Colonoscopy 2ww LGI (2ww LGI STT) for patients with suspected Colorectal Cancer (CRC), have been extensively implemented in the UK. Approximately 3.9% of patients referred via the 2ww LGI will get a new diagnosis of IBD; once CRC has been excluded however, there is no standardised pathway for the management of those newly IBD pts. We implemented in 2019 in our Trust a new service structure for rapid access of those new IBD patients to IBD clinics, with emphasis to Nurse Led IBD clinics. In this study we aimed to look at real world data for the management of those new IBD pts in a large district hospital. Methods Retrospective analysis of prospectively collected data for all newly (endoscopically) diagnosed IBD patients referred from the 2ww LGI STT service, between January 2019 and March 2020, at Chase Farm and Barnet Hospitals (BCF). Results There has been a steady increase over time in the number of new IBD pts identified via the 2ww LGI STT and referred to BCF IBD service. A total of 168 patients were referred to BCF IBD service via this pathway over the above 14 months. Within the first 2–4 weeks after colonoscopy, 86% patients were seen in the IBD Nurse led clinic. The remaining patients were seen within 6–8 weeks either in IBD Nurse or Consultants clinics. Approximately 11% of patients were not started on any medication at the time of colonoscopy. The remaining patients were commenced on either Steroid or 5ASAs post colonoscopy, in accordance with our local pathway. Biologic treatments or immunosuppressants were required for 18% of those patients during the above timeframe. Conclusion 2ww LGI STT identifies a significant number of newly diagnosed IBD patients in our Trust. 2WW LGI endoscopists of different levels and backgrounds (medical, surgical, nurses, fellows, insourced) should be aware of the first line IBD therapies and relevant IBD pathways, and prescribe those in Endoscopy Unit. Advanced Nurse IBD clinics are an integral part of the IBD service, especially for newly diagnosed IBD patients via the 2ww LGI STT.

P279 Potential of managed care programmes for patients with inflammatory bowel diseases – results from a large survey study among physicians and IBD-patients in Germany, Austria and Switzerland (the EASEIBD study)

Abstract Background IBD-care may be challenging and benefits from a multidisciplinary, cross-sectoral treatment approach and active patient involvement. However, occasionally there is a lack of patients′ empowerment and additionally, a necessity for the optimisation of physicians′ treatment is apparent. Furthermore, there is a deficiency in evidence regarding the effectiveness of structured care approaches (“managed care”) on patient-related outcomes (PROs). Therefore, our study aims to evaluate the potential of managed care programmes for IBD patients. Methods EASEIBD is a cross-border study conducted by IBD-DACH, an IBD working group in Germany (D), Austria (A) and Switzerland (Ch). Within the DACH-region, a cross-sectional survey of patients and physicians from IBD hospital-outpatient departments and gastroenterology practices was carried out. The questionnaire evaluated the effect of instruments and contextual factors of IBD-care with regard to quality of life (QoL). Additionally, the effects of “managed care” instruments were examined while considering centre-related structural characteristics. The analysis was performed using a multivariate multilevel regression model, controlled by various physician and patient characteristics. Results 2536 IBD-patients from 66 centres (643 IBD-patients/quarter; 31% hospital out-patient departments) were consecutively enrolled in EASEIBD (centres/IBD-pat.: D-52/1735; A-10/647; Ch-4/154). Overall, patient satisfaction (77-84%) (Fig. 1) as well as perceived quality of care (82-87%) (Fig. 2) was high and comparable in the descriptive analysis between German, Austrian and Swiss IBD-patients. Statistically significant differences were only found in single characteristics, e.g. in quality of life (EQ5D-VAS) (p=0.004) (Fig. 3). However, these do not appear clinically relevant with regard to the absolute values. In the entire DACH-region there were detectable effects of elements representing structural quality and assessments of the centres, with regard to the perceived quality of patient care (Fig. 4), whereby, in particular, a positive influence of web-based instruments (e.g. homepage) (p=0.040) and potential use of homecare calprotectin (0.046) had the most pronounced effect. Noteworthy, in Germany, the implementation of specialised IBD nurses was associated with a beneficial impact on patients′ QoL (0.027) when compared to the cumulative results from the entire DACH region (p=0.681). Conclusion Our study shows that the use of elements of managed care programmes resulted in a high process quality, which is evident from the reported high patient satisfaction and quality of care by IBD-patients in the entire DACH region, and qualifies this area as a suitable common study landscape.

P558 Medication Preference of 400 patients with mild to moderate Ulcerative Colitis

Abstract Background Patient adherence to his/her medication is a major challenge in the successful management of any chronic disease and it is a major challenge in Ulcerative Colitis (UC). Patient adherence is thought to be closely related to patient preference of medication and formulation used. We wanted to investigate the patient preference between tablets and granules of mesalazine and compare it to the physician perception. Methods We conducted an online survey between November and December 2020 in 4 EU countries (France, Germany, Spain, and the UK). In addition to patients and physicians from these 4 countries, the questionnaire was also addressed to IBD nurses from the UK. Patients were included if they had mild or moderate UC. Results 400 patients, 160 physicians, 20 nurses participated in this survey. 68% patients were taking tablets and 32% granules. 62% of the patients who answered the survey admitted their preference for tablet while only 38% for granules (figure 1). 63.9% of the physician would prefer to prescribe tablets for their patients. Physicians stated that patients tend to be more adherent to tablets than granules (69% vs. 31%) and patients tend to find this the most convenient formulation. When patients were asked about some positive attributes of tablets, the highest agreement was with “good size, easy to see and handle” (7.6/10) while for granules “no problem to take granules in public” (8.4/10). When asked about some negative attributes of tablets, the highest agreement was with “I would like to take fewer each day” (6.1/10) and “I wish I could take fewer at a time” (5.4/10) while for granules “you have to drink a lot of liquid for them to go down” (6.6/10) and “I wish I could take fewer” (5.1/10). 50 patients were switched to tablets after trying granules first and 45 to granules after trying tablets. Treatment changes were initiated mainly by the physician (57% of the time). Patients switching to granules almost all agreed that they wanted to take fewer tablets each day (8.1/10). Patients switching to tablets complained about the need to drink a lot of water with granules (6.5/10) or to mix them with food (6.3/10). This is also reflected in the way patients take tablets (figure 2) or granules (figure 3). While 71% of the patients swallow the tablets whole only 35% of the patients swallow all the granules at once. 37% mix the granules with food or liquid, 20% divide the portions to be able to swallow them and 8% chew the granules. Asked about adherence, only 21% (85 patients) admitted taking less than 80% of prescribed medication. Conclusion The majority of the patients prefer the tablet formulation. A high strength tablet overcoming the pill burden could be a good solution to address patient expectations.

N04 Being an IBD Clinical Nurse Specialist in the UK National Health Service: Challenges, Stressors and Coping Mechanisms

Abstract Background Inflammatory Bowel Disease Clinical Nurse Specialists (IBD-CNSs) provide essential therapeutic and emotional support services to patients with often complex disease. The ever-increasing role expectations, treatment modalities and rising patient population places significant demands on IBD-CNSs (Stansfield, 2019), many of whom enter the role soon after qualifying. Posts in the UK-based RCN IBD Nurse Facebook© page suggest stress is high amongst members. Sustaining IBD-CNSs wellbeing is essential for ensuring sustainability of services. Our aim was to explore experiences of being an IBD-CNS in the UK, in order to inform the wider dialogue around workforce and the wellbeing of specialist nurses. Methods This hermeneutic phenomenological study used purposive sampling with maximum variation to recruit Band 6–8 IBD-CNSs who currently, or until recently, worked in NHS Trusts across the UK. Data were collected between July and September 2020, via online or telephone interviews. Focussing on personal perceptions, participants were invited to ‘Tell me what it means to be an IBD-CNS’ with follow-up prompts and probes as needed. Diekelmann et al’s (1989) team analysis method was used. Results Twenty-five IBD-CNSs participated [92% Female; Band 6 (n=3), Band 7 (n=10), Band 8 (n=13); 0.5–19 (mean 5.8) years in post; ex-NHS (n=4)]. Two constitutive patterns: ‘Giving and receiving support’, and ‘Developing potential’ were revealed, informed by relational themes addressing patients’ needs, service design/delivery challenges, workload, professional development opportunities, and peer support. Junior IBD-CNSs worried more about workload and learning the role, whilst senior nurses often struggled with the shift towards management responsibilities which they were expected to take on often without any managerial skills or training. The IBD-CNS role was often poorly understood by senior service managers, whose level of support varied widely. Some participants had techniques to mitigate against stressors, but there were also limited professional development opportunities especially in senior roles. Conclusion IBD-CNSs are committed to patients, despite an often-burdensome workload. Structural, institutional, and hierarchical issues undermine confidence. Many IBD-CNSs are stressed by mixed messages of delivering an excellent service yet being criticised/under-appreciated by the system. Robust senior support structures lead to better experiences for IBD-CNSs. This work contributes to the UK and global data evidencing the need to pursue strategies which promote wellbeing of all specialist nurses.

P513 Assessment of quality indicators in The Swedish Inflammatory Bowel Disease Registry (SWIBREG) for Crohn’s Disease treated with biological therapies

Abstract Background The development and clinical application of quality indicators (QI) for IBD are objectives of The Swedish inflammatory bowel disease registry (SWIBREG)(1). These include objective and subjective parameters aiming to standardise IBD care in Sweden(2).We aimed to evaluate QI target attainment at Karolinska University Hospital, and to identify specific patient or disease parameters associated with failure to reach QI targets. Methods QI targets as defined by SWIBREG were analysed in patients with Crohn′s disease undergoing treatment with biologics. A retrospective register-based study included 292 patients who received biological treatment between 2018-08-01 and 2020-01-31. Pediatric Crohn’s patients and patients with a treatment duration <6 months were excluded. Results Faecal Calprotectin (FC) and Haemoglobin (Hb) values were registered for 80% and 86%, respectively. Anaemia prevalence was 30%. Significantly lower monitoring frequencies were observed in patients undergoing treatment with Adalimumab and patients with biological treatment duration >1 year. FC was <250 μg/g in 77% of patients. The QI target for the frequency of Short Health Scale (SHS) registration was met whereas that of Physician Global Assessment (PGA) was not. The QI target for the most recent value of both SHS and PGA were met. Only 70% of smokers, 72% of patients with biological treatment duration >1 year and 52% of adalimumab patients had a registered SHS evaluation. Conclusion Adalimumab treatment, treatment duration and smoking are associated with decreased frequency of registration of QIs. Efforts are needed to ensure quality of care for these groups. A lower rate of PGA monitoring may reflect a lack of capacity for physician assessments and could be complemented with “professional global assessments” by specialist IBD nurses.

A81 BARRIERS AND FACILITATORS OF PEDIATRIC TO ADULT TRANSITION IN IBD: A PILOT STUDY EVALUATING THE STAKEHOLDER EXPERIENCE

Abstract Background Inflammatory bowel disease (IBD) is increasing in prevalence with up to 25% of IBD patients diagnosed before 18 years of age. These patients will require graduation from pediatric care to adult services. The transition of care from pediatric to adult gastroenterologists (GIs) is a purposeful transition that requires planning with involvement of all stakeholders to ensure proper transition and avoid interruption in care. Aims To identify the transition experiences of adult patients with pediatric diagnoses of IBD, their parents, pediatric and adult GIs and registered nurses (RNs) and identify barriers and facilitators to a successful transition. Methods Patients aged 18–25 diagnosed with pediatric-onset IBD were included. Semi-structured focus groups were held with 9 patients and separately with 4 parents. Questions focused on the patient transition experience, opportunities for improvement, and patient quality of life. Transition practices and expectations of 12 adult GIs, 7 pediatric GIs and 9 IBD nurses were also investigated in a series of provider specific focus groups. The groups were audio-recorded, transcribed and qualitative themes were noted. Results Patients: Facilitators included ease of access to adult providers outside of clinic time and parental presence in the early stages of transition. Barriers included abrupt transitions to adult care by age 18, lack of choice regarding adult GI and lack of adult nursing. Parents: Facilitators included an extended transition period, availability of support groups/resources. Barriers related to exclusion from the transition process and lack of input on adult GI choice. RNs: Facilitators include having champion IBD nurses on the pediatric and adult side during transition. Barriers included lack of educational tools for patients. Pediatric GIs: Facilitators included effective communication between adult and pediatric GIs, having an emergency assessment protocol, involving families in the transition process and access to multidisciplinary resources. Barriers included prolonged wait time for transfer and lack of adult access to multidisciplinary support. Adult GIs: Facilitators included succinct transfer summaries and formal transition programs for high risk patients. Barriers included a lack of multidisciplinary support, difficulty reaching rural areas, heavy case loads and prolonged wait time to transfer of care. Conclusions This study explores the stakeholder experience of pediatric to adult transition in IBD. Themes noted related to efficient communication between GIs, streamlining transfer summaries, ensuring a gradual transition process, involving parents and ensuring access to multidisciplinary resources. Identifying barriers and facilitators during the transition process can provide insight into creating a successful pediatric to adult transitions program in IBD. Funding Agencies None

Maternity leave as a specialist nurse

Michelle Goringe, IBD Nurse Specialist at York Teaching Hospital, recalls the challenges of taking time off and returning to work as a new mother

P258 Managing an ever-increasing inflammatory bowel disease helpline service

Abstract Background Inflammatory bowel disease helplines have been initiated by Trusts throughout the country over many years. However many of them are not adequately job planned and have also seen a dramatic rise in calls over the years. Our Trust operates a helpline over 3 acute hospital sites. Previously calls were not accounted for financially and calls not documented in patient notes. Methods The nurses on each site utilise a standard form that notes the issues that patients contact the helpline for and the outcome of the call. The consultation is then dictated via a speech recognition system and a letter is generated and sent to the general practitioner. All calls are then added to a central spreadsheet which then categorises the calls into flare advice, medicines advice, investigation issues, appointment issues, etc.. The time that the call takes is also noted, to enable better job planning. Results The monitoring of these helpline calls have enabled the team to employ 2 further IBD nurses as the income generated has paid for them. It has also enabled better job planning and it has highlighted the increased number of calls that are taken by the nursing team and that they have been safely managed and accounted for. it has also enabled the team to trend the calls that are taken and the reasons why patients phone our helplines. Conclusion This project has shown a dramatic increase in activity for the IBD nurses. It has also highlighted the financial activity of the service and the contribution this provides to the gastroenterology department. This audit has since been utilised by the South East IBD Network.

Inflammatory bowel disease standards updated for 2019

Lisa Younge, Lead IBD Nurse at the Royal London Hospital, introduces some key features of the new standards from IBD UK

Sa1753 – IBD Nurse Intervention for Patients Assigned to Biologic Therapy Decreases Uncertainty and Improves Patients' Reported Outcomes

Sa1753 – IBD Nurse Intervention for Patients Assigned to Biologic Therapy Decreases Uncertainty and Improves Patients' Reported Outcomes

Health Care Transition Outcomes in Inflammatory Bowel Disease: A Multinational Delphi Study.

BackgroundTransition programmes are designed to prepare adolescent inflammatory bowel disease [IBD] patients for transfer to adult care. It is still unclear which outcome parameters define ‘successful transition’. Therefore, this study aimed to identify outcomes important for success of transition in IBD.MethodsA multinational Delphi study in patients, IBD nurses, and paediatric and adult gastroenterologists was conducted. In stage 1, panellists commented on an outcome list. In stage 2, the refined list was graded from 1 to 9 [least to very important], by an expert and a patient panel. In stage 3, the expert panel ranked important outcomes from 1 to 10 [least to most important]. Descriptive statistics and Mann–Whitney U-tests were performed.ResultsThe final item list developed in stage 1 was tested by the expert [n = 74 participants, 52.7% paediatric] and patient panel [n = 61, aged 16–25 years, 49.2% male]. Respectively, ten and 11 items were found to be important by the expert and patient panel. Both panels agreed on eight of these items, of which six reflected self-management skills. In stage 3, the expert panel formed a top-ten list. The three most important items were: decision-making regarding IBD [mean score 6.7], independent communication [mean score 6.3] and patient satisfaction [mean score 5.8].ConclusionThis is the first study identifying outcomes that IBD healthcare providers and patients deem important factors for successful transition. Self-management skills were considered more important than IBD-specific items. This is a first step to further define success of transition in IBD and subsequently evaluate the efficacy of different transition models.

Integrated Care Models: Optimizing Adult Ambulatory Care in Inflammatory Bowel Disease.

BackgroundInflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a chronic, complex and unpredictable disease affecting an increasing number of patients worldwide from a young age. Inflammatory bowel disease is associated with multiple comorbidities and complications, requiring ongoing preventative, acute and chronic care. The purpose of this article is to review the literature on outpatient care models used to treat adults with IBD and to gain insight on how to improve quality of care and reduce costs.MethodsA comprehensive review of recent literature on PubMed, Scopus and Google Scholar databases about care models used to treat IBD was performed. Key terms included ‘inflammatory bowel disease’, ‘organizational models’, ‘patient care team’ and ‘quality improvement’.ResultsStudies showed that an integrated care model decreases hospital admissions, IBD-related surgeries and comorbidities of IBD, ultimately decreasing direct and indirect costs of IBD compared with a more traditional patient-physician model. A gastroenterologist-led multidisciplinary team (MDT) involving comprehensive care by IBD nurses, a surgeon, psychologist, dietician, pharmacist, and other members as needed is recommended.ConclusionsA holistic approach to IBD care delivered by a MDT with structured monitoring, active follow-up, patient education and prompt access to care improves outcomes for IBD patients. More research is needed on the cost-effectiveness of integrated care models to demonstrate long-term value and secure funding for implementation. Future research should compare integrated models of care and assess patient and physician satisfaction in these models of delivering IBD care.

More nurses, better care

Isobel Mason discusses the value and influence of the inflammatory bowel disease nurse specialists and the background and impact of the ‘More IBD Nurses – Better Care’ campaign

N026 IBDoc® self-care/point-of-care calportectin test: Early value in a district general hospital inflammatory bowel disease service

Faecal Calprotectin samples at the trust are a current send away test. These can take 3–6 weeks to come back and while the value of the result is high even with these lead times; a faster result is desirable. Patients who may be having distressing symptoms and the trust can benefit. Initiating treatment quickly avoiding admission and the spiralling costs seen in IBD patients who are admitted to hospital.1 The test requires access to a smart phone by the patient, they need to download an App called IBDoc® and calibrate their camera. (i) The plan is to use the kit in two ways to maximise the benefits. (ii) As a point of care with the sample being collected by the patient and the test carried out by the IBD nurses. (iii) As a self-test. 18 tests were provided to trial and one of the nurses underwent face-to-face training, this took backed up with online support materials. The IBD Nurse found the training to be effective it took approximately 20 min’s of an IBD nurses time to carry out the test. The results were compared using the same stool sample to send away to the current provider. Of the tests, 15 were completed, discrepancies between results (Figures 1 and 2) have two likely reasons. Tests completed by IBD nurse. Tests completed by IBD nurse. Tests completed by patients. Tests completed by patients. First, the IBDoc® results are higher this is thought to be because of the freshness of samples. Individuality of calprotectin results was noted by one study2 not just between individuals but between samples taken at different times of day from the same person. Secondly, the assays used are different and a different result is expected because of this. Comparing the two has helped us understand the new results and will allow us to interpret future results effectively. A small survey of the patients was conducted seven patients that responded found the test easy to use and thought it had improved their access to treatment. The results in Figure 1 shows that at least one hospital admission was avoided, as a fast-track of treatment to Infliximab occurred. The IBDoc® adds value to patient care, it enhances the patient’s journey allowing quick treatment decision to be made saving at least 1 hospital admission during this small trial of the product. Patients reported that they felt their care was enhanced because of it. Using this test with remote monitoring software may save the need for face-to-face follow-up. 1. Ghosh N, Premchand P. A UK cost of care model for inflammatory bowel disease. BMJ, 2015;6:169–74. 2. Lasson A, Stotzer PO, Öhman L, et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohn's Colitis, 2014;9:26–32.

N027 Telephone/email service provided to IBD patients by Canadian IBD nurses

N027 Telephone/email service provided to IBD patients by Canadian IBD nurses

NO002 Increasing research capacity of IBD nurses across Europe—a case study of Inflammatory Bowel Disease Fatigue (IBD-F) scale translation and validation

NO002 Increasing research capacity of IBD nurses across Europe—a case study of Inflammatory Bowel Disease Fatigue (IBD-F) scale translation and validation

LOGIC Education telephone advice module: IBD nurses give their views

Gastrointestinal NursingVol. 15, No. 9 AdvertorialLOGIC Education telephone advice module: IBD nurses give their viewsKath Phillis, Lynda Gardiner, Gayle MartinKath PhillisSearch for more papers by this author, Lynda GardinerSearch for more papers by this author, Gayle MartinSearch for more papers by this authorKath Phillis; Lynda Gardiner; Gayle MartinPublished Online:16 Nov 2017https://doi.org/10.12968/gasn.2017.15.9.6AboutSectionsView articleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareShare onFacebookTwitterLinked InEmail View article FiguresReferencesRelatedDetails 2 November 2017Volume 15Issue 9ISSN (print): 1479-5248ISSN (online): 2052-2835 Metrics History Published online 16 November 2017 Published in print 2 November 2017 Information© MA Healthcare LimitedPDF download